Molecular determinants regulating the activation of class B G-protein-coupled receptors (GPCRs) by native peptide agonists are largely unknown. We have investigated here the interaction between the corticotropin releasing factor receptor type 1 (CRF1R) and its native 40-mer peptide ligand Urocortin-I directly in mammalian cells. By incorporating unnatural amino acid photochemical and new clickchemical probes into the intact receptor expressed in the native membrane of live cells, 44 intermolecular spatial constraints have been derived for the ligand-receptor interaction. The data were analyzed in the context of the recently resolved crystal structure of CRF1R transmembrane domain and existing extracellular domain structures, yielding a complete conformational model for the peptide-receptor complex. Structural features of the receptor-ligand complex yield molecular insights on the mechanism of receptor activation and the basis for discrimination between agonist and antagonist function.
INTRODUCTION
G-protein-coupled receptors (GPCRs) comprise a superfamily of eukaryotic transmembrane proteins that are critical for the conversion of a vast array of extracellular signals into intracellular responses. Because of their key role in the regulation of major physiological and pathophysiological functions in living organisms, GPCRs are highly relevant targets for pharmacological intervention. To that end, it is of fundamental importance to acquire structural information of GPCRs and to understand how they interact with their cognate ligands at the molecular level. GPCRs consist of a bundle of seven transmembrane (7TM) helices connected by intracellular (ICLs) and extracellular loops (ECLs), flanked by an N-terminal extracellular domain (ECD) and a C-terminal cytosolic tail. Despite the impressive development of GPCR crystallography techniques over the last few years, full-length structures have been solved only for class A GPCRs mostly bound to small-molecule ligands (Katritch et al., 2013) . Only two receptors have been characterized so far in complex with peptide ligands, both of short length (White et al., 2012; Wu et al., 2010) .
Class B GPCRs are a family of 15 peptide receptors of high pharmacological relevance to widespread diseases, such as diabetes (glucagon and glucagon-like peptide-1 [GLP1] receptors) and osteoporosis (parathyroid hormone [PTH] receptor and calcitonin receptor) (Pal et al., 2012) . Class B GPCRs have large ECDs (100-160 amino acids), which serve as major sites for selective recognition of peptide ligands. Structural data for class B receptors are limited to partial domains, including the structures of several ligand-bound ECDs and the two very recent structures of the 7TM domains of the corticotropin-releasing factor receptor type 1 (CRF1R) and the glucagon receptor (GCGR), both of which lack the ECD and are bound to small-molecule antagonists (Hollenstein et al., 2013; Siu et al., 2013) . Although a conserved pattern has been identified for binding of the C-terminal segments of peptide ligands to the ECDs of class B GPCRs, little is known about how the ligand's N terminus interacts with the receptor's 7TM domain to trigger downstream signaling events (Pal et al., 2012; Parthier et al., 2009) . By modulating the basal and stress-induced secretion of adrenocorticotropic hormone, b-endorphin, and other proopiomelanocortin-related peptides from the anterior pituitary, CRF1R acts as the key regulator of an organism's response to stress stimuli. Molecules antagonizing CRF1R activity have been long sought after for the treatment of chronic stress, anxiety, and depression (Hemley et al., 2007) . Understanding how native peptide ligands activate CRF1R can provide precious leads for the development of novel effective therapeutics.
Ligand-receptor interactions at class B receptors have been intensively investigated with conventional photoaffinity crosslinking Pham and Sexton, 2004; Wittelsberger et al., 2006) . In the past, photoactivatable moieties could be inserted into peptide ligands only, which often affects their native binding and pharmacological properties (Beyermann et al., 2007) and limits the study to a few tolerant sites-lacking data especially in the 7TM region in which receptor activation takes place ( Figure S1 available online). We have recently demonstrated that the genetic incorporation of photocrosslinking amino acids into the GPCR itself is well tolerated at many sites and allows specific crosslinking of peptide ligands (Coin et al., 2011) . We report here a systematic investigation of the interaction between CRF1R and one of its native ligands, the 40-mer neuropeptide Urocortin-I (Ucn1) (Vaughan et al., 1995) , based on the systematic genetic incorporation of photochemical and click-chemical probes into the receptor. We have revealed the binding path of the peptide agonist in the 7TM domain and have identified hallmarks of structural elements of CRF1R from the native environment of the live cell. A detailed conformational model for the CRF1R-Ucn1 complex based on the many ligand-receptor interactions determined here eventually revealed unique features of peptide ligand binding to class B GPCRs and provided new insights into the potential mechanism for receptor activation.
RESULTS

Mapping the Ucn1 Binding Interface on CRF1R via Photocrosslinking in Live Cells
Our strategy to map the ligand-receptor interface directly in mammalian cells is to genetically incorporate a photocrosslinking unnatural amino acid (Uaa) into the receptor at each position throughout the putative domain of interaction. If the ligand is proximal to the Uaa in the associated complex, it is covalently captured by the crosslinking moiety upon UV irradiation and can be detected in correspondence of the molecular weight (MW) of the receptor-ligand adduct in western blot (WB) ( Figure 1A) .
We have previously incorporated the photocrosslinking Uaa p-azido-phenylalanine (Azi, Figure 1B ) into CRF1R expressed in HEK293T cells in response to the amber stop codon TAG using an amber suppressor tRNA derived from E. coli tRNA Tyr and an enhanced synthetase (E2AziRS) specific for Azi (Takimoto The formed nitrene inserts unspecifically in C-H and heteroatom-H bonds within an estimated radius of 3 Å (i.e., 9 Å from the Cb of Azi) (Grunbeck et al., 2012 ) (see also Figure S4B ). (C) Plasmids for expression of Azi-CRF1R mutants in mammalian cells. Azi is incorporated in response to a TAG codon substituted into the receptor gene. The monomeric cassette for tRNA expression is shown under pIre-Azi3. The tRNA Bst-Yam gene is flanked by the U6 promoter and a 3 0 flanking sequence for correct processing in mammalian cells (Wang et al., 2007) . (D) Amino acid sequences of selected CRF1R ligands. All peptides are C-terminally amidated. Ucn1 and CRF are endogenous agonists in human and rat; Svg (Sauvagine) is the frog homolog. Ast (Astressin) is a synthetic antagonist derived from CRF, containing D-Phe (f), norleucine (X), and a lactam bridge (black line).
(E) Specific crosslinking of native Ucn1 by N123Azi-CRF1R. WB of cell lysates resolved by SDS-PAGE probed with aUcn1 antibody (left) to detect the ligand covalently crosslinked to the receptor and with aFlag antibody (right) to detect the receptor containing a C-terminal Flag tag. Fully glycosylated CRF1R (mature form at the cell membrane) runs at apparent MW 65-75 kDa. The narrower band at 50 kDa represents the high-mannose glycosylated receptor not yet exported to the surface (Coin et al., 2011) . Nonglycosylated CRF1R runs at apparent 37 kDa. The asterisk denotes one-third total protein loaded; the double asterisk denotes sample deglycosylated with Peptide N-Glycosidase F (PNGaseF). See also Figure S1 . et al., 2009 ). This system permitted photocrosslinking experiments with CRF1R mutants containing Azi in the ECD but yielded very low Azi incorporation in other receptor regions (Coin et al., 2011) . We devised here a more efficient system in which the amber suppressor tRNA derived from B. stearothermophylus tRNA Tyr (Bst-Yam) (Sakamoto et al., 2002) was driven by the type 3 polymerase III promoter U6 (Wang et al., 2007) . Three tandem repeats of the tRNA cassette were built into a plasmid coexpressing E2AziRS ( Figure 1C ), which was cotransfected into HEK293T cells with a second plasmid expressing CRF1R fused to a Flag tag at its tolerant C terminus (Coin et al., 2011) . We achieved yields of Azi-CRF1R mutants up to 30% of wild-type (WT) ( Figure 1E , lanes 10 and 12), corresponding to the intrinsic efficiency limit for stop codon suppression (Sakamoto et al., 2002) . Intact cells expressing the Azi-CRF1R were incubated with unmodified CRF1R agonist Ucn1 ( Figure 1D ) and were irradiated at the binding equilibrium with UV light (365 nm). Crosslinked samples were resolved with SDS-PAGE and immunoblotted with an aUcn1 antibody. A distinct Ucn1-specific band at the MW corresponding to the receptor-ligand adduct was detected for a crosslinking hit N123Azi-CRF1R ( Figure 1E , lane 6). To demonstrate that only specifically bound Ucn1 is captured by Azi, the CRF1R antagonist Ast ( Figure 1D ) (Gulyas et al., 1995) was added as a competing ligand. The crosslinking signal decreased gradually with increasing amounts of Ast and disappeared when a 100-fold excess of competitor was applied ( Figure 1E , lanes 6-9). Cells expressing WT CRF1R and nontransfected cells irradiated in the presence of Ucn1 did not give detectable crosslinking bands ( Figure 1E , lanes 1-2). Likewise, no crosslinking was observed either in the absence of ligand or when omitting UV irradiation ( Figure 1E , lanes 3-4).
With the improved expression system, we were able to incorporate Azi systematically throughout all positions of the juxtamembrane region (J region) of CRF1R, including the three ECLs and the extracellular halves of the TM helices, as well as the hinge region joining helix I to the ECD ( Figure 2C ). As a control, we also tested a subset of positions in the ECD, chosen on the basis of ECD structures (Pioszak et al., 2008; Grace et al., 2010; Pal et al., 2010 Table S1 ) (Wootten et al., 2013) . We detected Ucn1-specific bands at the MW of the receptorligand adduct for 35 mutants, indicating that Ucn1 crosslinked at these receptor sites (Figure 2A ). Crosslinking was identified at Y73 in the ECD, as previously observed using a radiolabeled Ucn1 analog (Coin et al., 2011) . In the TM region, clusters of three to four crosslinking sites were identified at the tips of all helices except helix IV, mostly at an interval of three to four residues (Figure 3A) . The same pattern was observed at the tip of helix I through the hinge region from N123
1.43 to K113 1.33 , followed by three adjacent hits at K111-K110-E109. Crosslinking sites were also found in ECL2 and ECL3, with K262 ECL2 giving a particularly intense signal.
As a further control, we evaluated the binding properties of all Azi-CRF1R mutants using a photolabeling reaction with Bpa 12 -Ucn1, a Ucn1 analog that contains the photocrosslinking p-benzoyl-phenylalanine (Bpa) and binds to CRF1R with high affinity (Kraetke et al., 2005) . Most Azi mutants were labeled by Bpa 12 -Ucn1 in a comparable range of intensity, with only two mutants (I51 ECD and V97 ECD ) giving no detectable labeling ( Figure 2B ). Positive labeling by Bpa 12 -Ucn1 assesses that, for most Azi-CRF1R mutants that did not capture Ucn1, lack of crosslinking was not due to deficiency of ligand binding.
Overall, the photocrosslinking results provide an unprecedented panoramic map of the receptor regions coming in proximity of the bound ligand ( Figure 3A ), which comprises partial binding regions inferred from previous mutagenesis studies ( Figure S2B ). To gain a 3D overview of the ligand binding path, we highlighted the 35 crosslinking positions on the structure of the 7TM domain of CRF1R (Figures 3B-3E) (Hollenstein et al., 2013) . The 35 hits are distributed along the J region not only at the level of the ECLs but also as deep as two to three helix turns down the 7TM helices, thus delimiting a relatively deep and very broad binding pocket, which spreads across the whole space enclosed in the TM helix bundle.
Determining the Position of Ucn1 in CRF1R via Proximity-Enabled Chemical Crosslinking
To position Ucn1 in the 7TM binding pocket, we sought to pinpoint specific pairs of ligand and receptor residues proximal to each other. Intermolecular proximity points can be derived through disulfide bond formation between Cys residues introduced into both the ligand and the receptor (disulfide trapping) (Dong et al., 2012; Monaghan et al., 2008) . The disulfide linkage, however, does not survive the reducing condition in SDS-PAGE analysis, which was necessary to achieve complete separation of noncrosslinked Ucn1 from the reaction mixture ( Figure S3A ). We have recently demonstrated a biocompatible click reaction between Cys and the Uaa p-2 0 -fluoroacetylphenylalanine (Ffact) (Xiang et al., 2013) , which takes place only when the two residues are in close reciprocal proximity and forms a covalent bond stable in reducing SDS-PAGE ( Figure 4A ). Here, we determined points of proximity between Ffact incorporated into the receptor and Cys introduced into the ligand ( Figure 4B ).
Ffact was incorporated into CRF1R at the 23 sites that yielded the most intense signals in Azi-photocrosslinking. Cys was introduced into Ucn1 by substituting the hydrophilic residues at sites 6, 8, 10, 12, and 14 based on the following considerations: (1) the activation determinants of Ucn1 are included in the segment 5-16, which is expected to interact with the 7TM of the receptor (Beyermann et al., 2000; Nielsen et al., 2000; Rivier et al., 1983) ; and (2) within the alternating hydrophilic-hydrophobic amino acid pattern of this segment ( Figure 1D ), substitution of the hydrophobic residues with Ala almost abolishes ligand activity, whereas hydrophilic residues are relatively tolerant (Kornreich et al., 1992) . To assess whether Cys 6 -, Cys 8 -, Cys 10 -, Cys 12 -, and Cys
14
-Ucn1 bind CRF1R, the analogs were applied to three receptor mutants bearing Azi in different domains (Y73Azi-, Y116Azi-, and K262Azi-CRF1R) for Azi-photocrosslinking. See also Table S1 .
Indeed, all five ligands produced crosslinking bands of similar intensity to that of WT Ucn1 with all three receptor mutants ( Figure S3B ). Intact HEK293T cells expressing each Ffact-CRF1R mutant were incubated with each Cys-Ucn1 analog for a total of 115 combinations. Cell lysates were resolved on SDS- (A) Snake plot of rat CRF1R with TM domains based on the CRF1R crystal structure (Hollenstein et al., 2013) . ''Y'' denotes glycosylated residues. Bold squares highlight the most conserved residues through class B GPCRs (Wootten et al., 2013) . Red circles represent residues substituted by Azi; full magenta circles represent crosslinking hits, with the color shades roughly reflecting the intensity of the crosslinking bands detected in WB with the aUcn1 antibody. Azi-CRF1R mutants that were either not expressed at all or not labeled by Bpa 12 -Ucn1 are represented with full gray circles, whereas mutants that were poorly expressed or weakly labeled by Bpa 12 -Ucn1 are represented with half gray circles. Positions 33, 42, 51, 65, 71, 73, 77, 84, 93, 99, 116 , and 270 were investigated with radiolabeled ligands in (Coin et al., 2011) . (B-E) The crystal structure of the 7TM domain of CRF1R (Hollenstein et al., 2013 ) with Azi-crosslinking hits colored magenta. Shown are an overview of the domain from the membrane side (B), a view of the receptor surface from the extracellular space (D), and two side views of the pocket surface in the membrane plane, placing in the foreground helices II, III, IV, and V (C) and helices VI and VII (E). The receptor surface in (C) and (E) is clipped in front to allow a view inside the binding pocket. See also Figure S2 . PAGE under reducing conditions (100 mM dithiothreitol) and analyzed with immunoblotting. To normalize the click-reaction results with respect to the expression level and the binding properties of the Ffact-CRF1R mutants, each mutant was also photolabeled with Bpa 12 -Ucn1. The intensity of the photolabeling band was used as a standard to discriminate between hits of the Cys-Ffact click reaction (comparable intensity) and background signals (intensity < 1/10). Each Cys-Ucn1 analog reacted with a subset of Ffact-CRF1R mutants ( Figures  4C and 4D) . The results locate position 8 of the ligand at the receptor interface between helices V and VI, position 12 at the interface between helices VI and VII, and position 14 close to S349 7.43 in helix VII. This pattern clearly reveals that the ligand is oriented in the C to N direction stretching from helix I to VI ( Figure 4B) . No intense signals were detected with Cys 6 -or Cys 10 -Ucn1. Given that the alkyl C-S bond is 1.8 Å in length and the Ffact moiety is about 6.8 Å , we estimated the maximal Cb-Cb distance for the Cys-Ffact pairs undergoing the click reaction to be 9 Å ( Figure S4A ).
A 3D Model for Ucn1 Binding to CRF1R Supported by Numerous Experimental Constraints
The nine spatial constraints between specific residue pairs in CRF1R and Ucn1 derived from the Cys-Ffact click experiments (Table 1) were used in energy-based conformational modeling. Rat Ucn1 was docked into a flexible model of rat CRF1R generated by combining the crystal structures of human CRF1R ECD (Protein Data Bank [PDB]: 3EHU) (Pioszak et al., 2008; Pal et al., 2010) and of the thermostabilized human CRF1R 7TM domain (PDB: 4K5Y) (Hollenstein et al., 2013) . The two structural domains were connected by a flexible linker comprising residues 103-116. Of those, residues 112-116 were modeled as a helix analogous to the ''stalk'' region described in the crystal structure of the closely related receptor GCGR (Siu et al., 2013) . Ligands of the CRF family have a high propensity to assume helical conformation, as observed in nuclear magnetic resonance (NMR) studies of unbound Ucn1 and CRF (Grace et al., 2007; Romier et al., 1993) and inferred by studies on functional properties of CRF-related ligands (Beyermann et al., 2000; Rivier et al., 1998) . However, the finding that both Cys 12 -and Cys 14 -Ucn1 reacted with S349Ffact-CRF1R ( Figure 4C ) implies that both positions of the ligand point toward S349 7.43 in helix VII, a condition that cannot be satisfied within an a helix. Therefore, we introduced full backbone flexibility in residues 11-19 of Ucn1 during the docking procedure. Subsequent energy optimization of the complex included flexibility in all residues of the ligand and removed all distance restraints. In the resulting energy-optimized docking model, most residues of the Ucn1 peptide retain the expected a-helical conformation. All the imposed constraints from the Cys-Ffact reaction are satisfied-the eight distances between Cb atoms of the amino acid pairs are less than 9 Å , and one is 9.4 Å ( Table 1 and Figure S4C ), which is in close agreement with the expected value. In addition, five other proximal residue pairs in ligand and receptor independently derived from previous crosslinking experiments at CRF1R are well accommodated in the model, although they were not used as constraints during the simulation experiments (Table S2 ). The model is furthermore strongly validated by our Azi-photocrosslinking results. All 35 crosslinking hits lie in close proximity of the docked ligand, with distances between Cb atoms of crosslinking sites and nonhydrogen atoms of Ucn1 peptide not exceeding 9 Å (Figure S4C ), which is well within the estimated radius of reach of Azi ( Figure S4B ). One hallmark of the CRF1R 7TM crystal structure is a sharp kink around G356 7.50 , which tilts the extracellular portion of helix VII outward, away from the helical bundle (Hollenstein et al., 2013) (Figures S5A and S5B ). The intrinsic flexibility of the Gly residue, high crystallographic temperature factors, and the significant (2-3 Å ) deviations observed in the position of helix VII between the asymmetric subunits of the CRF1R crystal structure leave open the possibility of substantial movement of the extracellular portion of helix VII. Therefore, we introduced backbone flexibility in residues Q355 7.49 -G356 7.50 and a portion of ECL3. In the energy-optimized model, the extracellular tip of helix VII is indeed shifted inward by 3.1 Å with respect to the position observed in the crystal structure ( Figure S5C ). This movement helps to satisfy the Azi crosslinking distances for residues R341 7.35 and F344 7.38 and Cys-Ffact distance for I345 7.39 at the tip of helix VII, which otherwise were in the 11-13 Å range. The inward tilt also brings helix VII in closer proximity of the ligand, significantly improving hydrophobic and polar interactions between their side chains. Moreover, full conservation of G356 7.50 in class B GPCRs (Wootten et al., 2013) and intolerance of this position to Azi substitution (Figure 2 ) suggest that this point of flexibility is required for correct receptor folding and probably plays a special role in receptor function. Docked Ucn1 shows a major C-terminal helical segment (V40-T16) interacting with the ECD and the hinge region of CRF1R ( Figures 5A and 5B) . The intermolecular contacts closely reproduce those observed in the crystal structure of CRF1R-ECD in complex with CRF (PDB: 3EHU), including the close proximity to Y73, which corresponds to an Azi-photocrosslinking hit. The midregion of the ligand runs antiparallel to the linker and the a-helical stalk of helix I ( Figure 5B ), which accounts for our Aziphotocrosslinking hits at E109, K110, K111, K113
1.33 , and Y116 1.36 . As it approaches the 7TM bundle, the ligand is about equidistant from helix I and the tip of helix II, which corroborates both the previously reported crosslinking of Bpa 17 -Svg (Sauvagine; Figure 1D ) to H117 1.37 in helix I and the crosslinking of (Table S2 ).
As Ucn1 enters the 7TM domain in the space between helices I, II, and VII, residues 13-15 form a short loop ( Figure 5C ), which accounts for the reactions of both C12 and C14 in Ucn1 with Ffact349 in helix VII. Following the loop, a second helical segment (H12-S6) spans the wide TM binding pocket to reach the interface between the extracellular end of helices V and VI ( Figure 5C ). Both helical segments of Ucn1 in the model are stabilized by intramolecular interactions-a salt bridge between R15 and E19 and an H-bond between H12 and D8, as observed in the NMR structure of the free ligand (PDB: 2RMF) (Grace et al., 2007 in six of the 7TM helices, respectively. The exception is helix IV, in which no interactions with the ligand were predicted by the model or observed by the photocrosslinking study ( Figures  3A and 5C ). Other residues of this Ucn1 region interact with CRF1R loops, including the cluster of hits centered on K262 ECL2 , and the stretch of residues L329 6.55 -N333 ECL3 and R341 7.35 around ECL3 ( Figure 5C ).
The ligand exits the TM region through a groove between the tips of helices V and VI, with the N terminus sticking outside the 7TM bundle ( Figure 5C ), which is consistent with the observation that Ucn1 tolerates very bulky N-terminal fusions ( Figure S4E ). The presence of two consecutive Pro residues at positions 3 and 4 assures an extended conformation in residues 1-5 of Ucn1, which accounts for Azi-photocrosslinking hits in this region (Y267 ECL2 , Y270 5.37 , and F331 ECL3 ) pointing outside the 7TM binding pocket.
DISCUSSION
Investigation of GPCR-Ligand Interactions under Native Conditions Using Genetically Encoded Chemical Probes
GPCRs are integral membrane proteins containing multiple domains and various posttranslational modifications. To understand GPCR-ligand interactions by crystallography, receptors have to be extracted from the cell membrane and modified with a series of expedients such as deglycosylation, therm-stabilizing mutations, fusions with soluble proteins, or complexes with stabilizing nanobodies. We present here a method to investigate GPCR-ligand interactions at the intact fully posttranslationally modified receptor bound to its WT ligand on the membrane of the live cell, which mimics the native conditions for GPCR function. We first genetically incorporated into the receptor the photocrosslinking Uaa Azi, which served as a proximity probe to provide an overall map of the ligand binding sites on the receptor. We then determined the relative position of the ligand in the binding pocket using a residue-specific chemical crosslinking reaction between Ffact genetically incorporated into the receptor and Cys introduced into the ligand. The derived intermolecular spatial constraints served eventually to build a detailed conformational model for the receptor-ligand complex.
Our optimized system for Uaa mutagenesis in mammalian cells allowed incorporating the unnatural probes efficiently and systematically through CRF1R. Out of 145 receptor mutants, only eight were not expressed or lost the ability to bind the ligand, yielding a 94% coverage of the screened positions. Both photoand chemical crosslinking hits could be distinctly identified by immunoblotting the captured native ligand, obviating radiolabels. Our strategy presents several advantages over traditional crosslinking methods. By introducing the photocrosslinker into the receptor rather than into the ligand, we could thoroughly investigate interactions in the 7TM region, which is hardly accessible with classic photocrosslinking experiments ( Figure S1 ). In addition, the Cys-Ffact crosslinking reaction takes place under reducing conditions and is irreversible. These properties allowed working in the presence of a reducing reagent to prevent self-dimerization of the Cys-Ucn1 analogs and to completely separate the nonreacted ligand on SDS-PAGE. Given the dynamic nature of ligand-receptor interactions, our Azi-and Cys-Ffact-crosslinking data likely depict a weighted average of receptor conformations involved in different stages of ligand binding and receptor activation. Faint crosslinking signals (e.g., K262Ffact; Figure 4C ) may represent assay background or transient conformations of the complex, but they were clearly discriminated from the strong signals (intensity < 1/10) and excluded from model building. Although models based on crosslinking data may not achieve a true snapshot of a single state like X-ray, they provide complementary information from a native system that is only minimally modified with a point mutation and on ensemble conformations that are valuable for understating dynamics and function. Overall, all 35 Azi crosslinking data are well satisfied by distances between the corresponding receptor residue and the ligand in the CRF1R-Ucn1 complex model, albeit generated using only nine Cys-Ffact pairwise distance restraints. Nearly all side chains of the 35 crosslinking hits point toward the docked ligand, except Y124
1.44 and L329 6.55 . The side chain of Y124 1.44 can still reach Ucn1 residues located in a wide gap between helices I and II, which explains its Azi crosslinking; crosslinking at L329 6.55 may be enabled by high conformational plasticity of this residue region proximal to the ECL3, which is disordered in molecules a and b of the CRF1R crystal structure ( Figure S5A ). On the other hand, some residues that lie in proximity of the docked ligand did not crosslink, which comprise potential ''false negatives'' ( Figure S4D ). Many of these residues point away from the ligand, whereas others may have conformations favoring intrareceptor crosslinking or solvent quenching (Coin et al., 2011) . Although any crosslinking technique can miss existing proximities, false negatives do not impact the quality of the modeling restraints, which are based solely on reliable positive crosslinking signals.
A Model for CRF1R-Ucn1 Binding Reveals Common and Divergent Features of Peptide Binding to Class B GPCRs
In the lack of full-length structures, there are continuous efforts to model class B GPCRs in complex with their cognate peptide ligands, including secretin (Dong et al., , 2012 , PTH (Monaghan et al., 2008; Wittelsberger et al., 2006) , and GLP1 receptors. Until now, such models have been limited by both the lack of structural data and the scarcity of spatial constraints for the critical TM region ( Figure S1B ). We have generated here a full-length model for the CRF1R-Ucn1 complex based on structural data for CRF1R and supported by about 50 experimental restraints, including 9 Cys-Ffact-click constraints, 35 Azi-crosslinking hits, and 5 independent restraints from the literature. The crosslinked residues line the 7TM binding cavity, which is much larger than in class A receptors or even in the class B receptor GCGR, allowing CRF1R to accommodate the horizontal helical segment of the ligand. We found both similarities and differences in the docking modes of Ucn1 in the current study and of glucagon with GCGR structure (Siu et al., 2013) or in the previous models of secretin and GLP1 binding to their receptors (Dong et al., 2012; Miller et al., 2011) . Although in all these models the peptides enter the receptor's J region almost vertically along helix I ''stalk,'' the paths of the peptide's N-terminal portion differ dramatically. Glucagon, GLP1, and secretin are expected to have an extended nonhelical stretch in residues 1-6, which places their N termini deep in the 7TM pocket. In contrast, all CRF1R agonists have much longer N-terminal segments, which have to maintain partially helical conformations and further extend between extracellular tips of helices V and VI to conform to the restraints derived from Cys-Ffact crosslinking. Therefore, although peptide ligands bind to the ECDs of class B receptors in a similar fashion, our results indicate that different binding paths are followed in the J region by peptides that have shorter N termini (secretin and glucagon like, <30 residues) and longer ones (CRF like, >40 residues).
Photocrosslinking Mapping of CRF1R Reveals Structural Features of Class B GPCRs in the Live Cell
The distribution pattern of photocrosslinking hits reveals information on structural elements of the receptor itself, unique in that they are derived from the native cellular context. The interval of 3-4 residues between crosslinking hits at the tip of the TM domains is consistent with the helical conformation of these segments observed in the CRF1R crystal structure. The lack of crosslinking in helix IV is then consistent with the position of helix IV at the periphery of the helical bundle observed in the crystal structures of CRF1R and other GPCRs, with no access to the binding pocket. Furthermore, the wide stretch of crosslinking hits at an interval of 3-4 residues found in the hinge region suggests that helix I extends above the level of other helices. Although this region is not resolved in the structure of CRF1R, the GCGR structure shows that helix I indeed extends up to the globular BRIL protein that substituted for the ECD. Our crosslinking data suggest that at least a part of this receptor ''stalk'' is present also in the ligand-bound full-length CRF1R in the live cell and might be a structurally conserved signature of class B GPCRs.
A marked difference between the crystal structures of CRF1R and GCGR, both representing receptors in an inactive state bound to a small-molecule antagonist, is the position of the extracellular tip of helix VII. In the CRF1R structure, the helix VII tip is tilted outward by about 10 Å (Figure S5B ), resulting in a binding pocket that is too wide for the Ucn1 peptide. Our model shows that a modest 3 Å inward tilt of helix VII around the flexible G356
7.50 dramatically improves the peptide fit in the pocket by allowing formation of an extensive interaction interface with both walls of the binding cleft. Moreover, this tilt also satisfies the crosslinking restraints for several residues in the helix VII tip, suggesting the possibility that a movement of the tip of helix VII is part of the peptide binding process, whereby the peptide stabilizes the more compact conformation.
An intriguing question for class B GPCRs concerns the orientation of the ECD relative to the 7TM bundle. In our model, the midregion of Ucn1 (approximately residues 26-16) runs antiparallel to the helix I stalk, with the helix-helix interaction being well supported by Azi-crosslinking hits at intervals of three to four residues within the stretch K113
1.33 -N123 1.43 . The three consecutive crosslinking hits at E109-K110-K111 suggest instead that this part of the ECD-7TM hinge assumes an extended conformation. Interestingly, in our model, this region of CRF1R corresponds to a modest kink in Ucn1 (residues 26-30) ( Figure 5B ), which is similarly positioned to kinks observed in NMR structures of other CRF-related ligands (Grace et al., 2007) . Overall, these results leave open the possibility for both the ligand and the receptor to accommodate a kink at the junction between the ECD and the receptor stalk, corroborating the hypothesis that the orientation of the ECD depends on the conformation of the ligand. Moreover, a series of weak crosslinking signals visible in WB at residues 106-108 and 112 ( Figure 2 ) supports a context of high flexibility in the whole solvent-exposed region 106-113 of the CRF1R binding site.
CRF1R Peptide Ligands: Conservation Pattern and Functional Insights
CRF1R from human and rodents is activated by endogenous peptide agonists (CRF and Ucn1), as well as by peptide homologs from other vertebrates (ovine CRF, carp Urotensin, frog Sauvagine). Sequence alignment shows two highly conserved regions in the N-terminal half (residues 3-22) and in the C terminus (33-38) of the ligands ( Figures 6A and 6B ), whereas the segment connecting the two conserved regions lacks any significant conservation, as do the very N-terminal residues. In our 3D structural model, the conserved regions of Ucn1 are indeed involved in extensive interactions with either the ECD or the 7TM domain of CRF1R, whereas the polar connector region and the ligand's N terminus are solvent exposed and have very limited contacts with the receptor (Figure 6C ), suggesting that the nonconserved regions are not directly involved in receptor recognition and activation. In fact, segment 21-31 of Ucn1 has been demonstrated to play a mere structural role in keeping the two segregated binding domains in the correct relative orientation (Beyermann et al., 2000) , and a functional role has been excluded also for the first three to four amino acids of CRFrelated peptides, which can be deleted without influencing agonistic properties of the ligands (Rivier et al., 1983 (Rivier et al., , 1984 .
Instead, from position 6 of CRF on, N-terminal truncations gradually reduce potency and activity of the agonist, eventually converting it into an antagonist with the deletion of residue 8, thus identifying segment 6-8 as crucial to achieve receptor activation (Rivier et al., 1984 (Rivier et al., , 1998 . The fact that, in our 3D model, the corresponding residues in Ucn1 (positions 5-7) are located in the groove between helices V and VI suggests that this interaction with the agonist triggers CRF1R activation, likely by inducing a movement of the two helices that rearranges the receptor from the unbound state to the active state. This effect cannot be exerted by peptide antagonists because they are too short to reach the interface between helices V and VI. Interestingly, small-molecule antagonists of CRF1R have been shown to bind in a deep TM pocket between helices III, V, and VI, probably hampering the natural activation movement (Hoare et al., 2006; Hollenstein et al., 2013) .
Conclusions
We have investigated the interaction between the CRF1R and its native peptide ligand Ucn1 by exploiting photo-and unique chemical reactivities of Uaas genetically incorporated into the receptor expressed in mammalian cells. The overall result is a detailed 3D binding model supported by about 50 experimental constraints, which unveils the binding path of the peptide agonist in the activation domain of the class B receptor and allows insight into its activation mechanism. Our method represents a major advance with respect to intrinsically limited and experimentally more demanding traditional photocrosslinking approaches and provides unique panoramic information derived from the full-length receptor in the native context of the live cell, which complements data derived from crystallographic characterization of isolated receptors in an artificial environment. Because Uaa incorporation imposes no restrictions on target sites or protein types, this strategy should be generally applicable to study protein interactions under native conditions.
EXPERIMENTAL PROCEDURES
Photocrosslinking HEK293T cells were cotransfected with plasmid pIre-Azi3 (expressing the BstYam tRNA and the E2AziRS specific for Azi) (Takimoto et al., 2009 ) and plasmid xxxtag-CRF1R-Flag (expressing CRF1R) in the presence of 1 mM Azi in the culture medium. After 48 hr, cells were harvested, and aliquots were incubated with either 100 nM Ucn1 or Bpa 12 -Ucn1 for 2 hr at room temperature (RT), followed by irradiation with a handheld UV lamp (365 nm, 8 W) for 40 min. Cells were lysed in 1% Triton X-100 buffer. Aliquots of cell lysates were denatured with 0.5% SDS and 400 mM DTT for 20-30 min at 37 C and deglycosylated with PNGase F at 37 C for 1 hr. Both deglycosylated and nondeglycosylated samples were resolved with denaturing SDS-PAGE (9%-10% acrylamide) and protein transferred onto a PVDF membrane. Blots were probed with monoclonal mouse anti-Flag M2-peroxidase conjugate (Sigma) to detect CRF1R. A homemade polyclonal aUcn1 antibody followed by a secondary arabbit-HRP conjugate was used to detect Ucn1. Signals were developed with SuperSignal West Pico Chemiluminescent substrate (Thermo Scientific).
Cys-Ffact Chemical Crosslinking
HEK293T cells were cotransfected with plasmid pIre-Keto3 (expressing the Bst-Yam tRNA and the EKetoRS specific for Ffact) (Takimoto et al., 2009) and plasmid xxxtag-CRF1R-Flag in the presence of 0.25 mM Ffact in the culture medium. Cells were harvested 48 hr later and split in six aliquots. Five aliquots were individually incubated with the five Cys-Ucn1 mutants (100 nM) in the presence of 1 mM tris(2-carboxyethyl)phosphine for 90 min. The sixth aliquot was incubated with 100 nM Bpa 12 -Ucn1 for 90 min, followed by irradiation for 20 min in a Spectrolinker XL-1500A (365 nm) at 4,400-5,000 mW/cm 2 . Samples were then processed and analyzed with WB as described for the photocrosslinking experiments.
Modeling
Energy-based conformational modeling of the CRF1R complex with Ucn1 was performed with ICM-Pro molecular modeling software (Molsoft LLC) based on the crystal structures of CRF1R ECD (PDB: 3EHU) (Pioszak et al., 2008; Pal et al., 2010) and 7TM (PDB: 4K5Y) (Hollenstein et al., 2013) domains. Regions not defined by the crystal structures-e.g., linker connecting the ECD and 7TM domain-or known to have high flexibility-e.g., Gly365-dependent kink around in helix VII-were treated as fully flexible. Peptide docking and energy optimization was guided by Ffact-CRF1R/Cys-Ucn1 chemical crosslinking data, introduced as soft harmonic tethers between Cb atoms of the corresponding residues. Global energy optimization of the complex in internal coordinates was performed by exhaustive conformational sampling of protein backbone in the flexible regions, as well as side chains (Grace et al., 2007) shows its propensity to form an a-helical fold. 
